Choosing a Medical Device Commercialization Pathway: Lean or Conventional
TL;DR
- Lean and conventional are not fast and slow. They differ in which risk you retire first.
- Pathway selection is a trade-off decision. Lean defers manufacturability and supply chain depth for capital efficiency to get you to market consuming fewer funds; conventional commits greater capital to develop a robust device ready for scale when you hit the market.
- Switching pathways later does not cancel what you deferred. You pay it under worse conditions. The cost to address technical debt climbs the later you pay the bill.
- Deferring deliberately can be right when capital is tight, as long as you track the debt and revisit at every gate.
Every development program leaves the concept phase with a route mapped to commercial scale. That route reflects what the team knows about the risks ahead and what it believes about the destination. Some founders commit early to the full destination and end up backtracking when the journey runs longer than planned. Others choose a nearer landmark first: a milestone product that proves the way forward, then a next generation once the route ahead is clearer.
Most medtech founders hear “lean” and think fast. They hear “conventional” and think slow. That framing misses what actually matters. The real decision behind any medical device development pathway is which risk you retire first: market and technical uncertainty, or operational and regulatory completeness. Get that sequencing wrong and you don’t just lose time. You take on debt that comes due at the worst possible moment.
Two Pathways to First Commercial Launch
A lean commercialization pathway and a conventional commercialization pathway lead to the same place. They just get there differently. Lean development defers aesthetic refinement, manufacturability work, supply chain hardening, and process maturity until the market hypothesis is proven. It prioritizes learning velocity and capital efficiency. That’s what early-stage teams need most while they’re still validating whether anyone will buy their device.
Conventional development advances commercial and manufacturing readiness in parallel with the design itself. It costs more up front and moves with more deliberation, but it produces a more complete operational asset sooner, which matters when capital allows for it or when a strategic acquirer is already at the table.
Neither pathway is the safer bet. Each is optimized for different constraints.
Every Medical Device Commercialization Pathway Creates Programmatic Debt
Here’s the part that rarely makes it into the pitch deck. Every pathway choice creates programmatic debt.
Choose lean, and you’re deferring design-for-manufacturing, design-for-serviceability, and deeper supply chain qualification. That debt doesn’t vanish. It comes due the moment you try to scale, usually all at once, usually more expensively than if you’d addressed it earlier.
Choose conventional, and you’re committing capital and time against a market thesis that might still be wrong. That’s a different kind of debt: sunk engineering and operational investment against a demand assumption you haven’t fully tested yet.
The debt doesn’t disappear if your circumstances change either. Switch pathways from lean to conventional and you don’t get to skip what you deferred. You service it retroactively, often under worse conditions than if you’d planned for it from the start. Get to an integrated prototype, or further, and you’re committed to an architecture that doesn’t translate to modular subassembly for efficient production. Recognize the need to prove your market too late, and you’ve already consumed precious capital needed to bridge the commercialization gap to scale.
Engineering cost-of-change research going back decades shows why timing matters this much. A design decision costs the least to resolve at concept or requirements. Wait until detailed design and the cost climbs by roughly an order of magnitude. Wait until verification, or worse, until after launch, and it climbs by another order of magnitude again. The exact multiplier isn’t medtech-specific and it varies by program, but the pattern holds everywhere it has been studied: the longer you defer a decision, the more it costs to resolve.
Applied to a pathway choice, that means the work you postpone gets resolved at the stage where it costs the most. But for a capital-constrained startup, deferring the manufacturing and supply chain work deliberately can be the only way to survive long enough to pay that debt down at all.
Funding and Product Market Fit Decide the Pathway
Before locking in a pathway, it’s worth answering a few questions honestly:
- How much runway do you have relative to your next funding milestone? What evidence secures your next funding round?
- Is your market hypothesis validated by real customer and clinical evidence, or is it still an assumption your team believes strongly?
- Is there already a strategic acquirer or later-stage investor in the conversation who will expect operational completeness, not just a working prototype?
- Does your device involve long-lead or specialized sourcing that would force supply chain decisions earlier than your development plan currently assumes?
If your answers reflect scarcity of funding, the need to prove there’s a market for your device, or you’re grappling with a novel technology, a lean development pathway takes you forward with greater capital efficiency. If your answers suggest technological maturity, a robust supply chain, and a path to manufacturing volume scalability with healthy gross margins, then conventional development gets you there. What your answers really tell you is which risk you can least afford to leave unaddressed right now.
Pathway Selection Is a Position to Revisit at Every Gate
Pathway selection isn’t a one-time decision made at kickoff and forgotten. It’s a position that should be revisited at every phase gate, because your risk profile changes as evidence accumulates. The founders who navigate this well aren’t the ones who picked the “right” pathway on day one. They’re the ones who understood what they were trading off, tracked what debt they were accumulating, and knew when the conditions had changed enough to warrant a different approach.
That’s a harder conversation than “lean versus conventional.” But it’s the one that actually determines whether your development program gets you to market with the evidence, the operations, and the capital position you need when you get there.
Julian Grove is Director, Digital Systems & Compliance at StarFish Medical. He earned his Bachelor of Engineering (BEng) degree in Mechanical Engineering from the University of Victoria and spent several years developing mechanical solutions for medical devices with StarFish while maintaining an eye for the overall system design.
Images: StarFish Medical
Related Resources
Lean or conventional? How to choose a medical device commercialization pathway based on funding and product market fit, and what each one costs later.
When one team designs, lays out, and brings up a board, knowledge sticks. Splitting that work across specialists looks efficient but creates the risk it’s meant to avoid.
AI coding agents like Claude and Codex are helping EE teams turn concepts into tested hardware in weeks, not months, without adding a new vendor or software dependency.
PCB stack-up shapes signal integrity, EMC performance, and manufacturability long before layout begins. Getting layers and reference planes right avoids costly redesigns later.
Explore Our Services
Our multidisciplinary teams have all the in-house capabilities to transform your medical device from concept to final product.
Medical device design and development with a commercial launch focus. See how we support clinical trials and facilitate seamless tech transfers.
We help you navigate complex regulatory landscapes to achieve commercial success. Explore our integrated approach to quality and regulatory services.